Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02889796 · ClinicalTrials.gov registry record · Phase 3
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,759
- Enrollment target
NCT02889796: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT02889796 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,759 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (128% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02889796, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,759 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Primary Outcome
ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity)participant's pai
Interventions
- DRUG Adalimumab
- DRUG Filgotinib
- DRUG MTX
- DRUG Placebo to match filgotinib
- DRUG Placebo to match adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,759 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 3 |
What the finished NCT02889796 record still lists
NCT02889796 is an interventional study that assigns participants to a tested intervention. Its 1,759 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (128% higher).
The record links to 0 conditions, and to 5 interventions - of which Adalimumab is the first listed.
NCT02889796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02889796 about?
NCT02889796 is a clinical study titled "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate". The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
What is the current status of trial NCT02889796?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,759 participants. The study started on 2016-08-30. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT02889796?
The interventions under investigation include: Adalimumab (DRUG), Filgotinib (DRUG), MTX (DRUG), Placebo to match filgotinib (DRUG), Placebo to match adalimumab (DRUG).
Who is sponsoring clinical trial NCT02889796?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02889796's enrollment target sits among peer trials
1,759 127th of 2000 higher than 1,873 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI